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1. Introduction 
Natural Killer (NK) cells were first defined, more than 30 years ago, on the basis of their 
unique capability of killing spontaneously different targets including tumor and virus-
infected cells. Thus, since their first discovery, NK cells came across as a potential attractive 
tool for the implementation of immuno-therapeutic strategies for different diseases. 
Accordingly, besides the plethora of studies aimed at investigating their functional and 
phenotypic properties, considerable efforts have also been spent in the past several years to 
understand how these cells could be generated and how their functions could be regulated 
and/or manipulated. At the same time further attention has been paid on their alteration in 
vivo and their potential role in the occurrence of NK cell-based hematological malignancies. 
2. NK cells: From a function to a multifaceted population 
2.1 The discovery of NK cells 
NK cells were originally identified on a functional basis. In the middle ‘70s, it was discovered 
that healthy individuals could display selective cytotoxic activity against tumor or virally 
infected cells and that this activity was hidden within the circulating lymphocyte population 
(West et al., 1977; Santoli et al., 1978). This implied the presence in the Peripheral Blood (PB) of a 
lymphocyte subset capable of killing different targets without previous sensitization. These 
cells, that for their functional properties were termed ‘Natural Killer’, were then characterized 
morphologically as Large Granular Lymphocytes (LGL) by virtue of their size and cytolytic 
granule content. Finally, in the late ‘80s, NK cells were more precisely defined with the CD3-
CD56+CD16+ surface immuno-phenotype. This also allowed the identification of the 
CD16/FcRIII as the receptor responsible for the Antibody-Dependent Cell Cytotoxicity 
(ADCC) function shown by NK cells (Lanier et al., 1986; Trinchieri, 1989). In the same period, 
the circulating NK cell population, which represented approximately 10-15% of PB 
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lymphocytes, was further split into CD56brightCD16dim/neg and CD56dimCD16bright cell subsets, 
expressing respectively low and high cytolytic properties. In the following 10 years great efforts 
were done to widen the list of NK cell markers and to define the surface receptors responsible 
for the regulation of NK cell cytotoxicity. Finally, in the last decade it was discovered that NK 
cells could exert different regulatory functions, and many studies were oriented to the 
definition of novel NK cell subsets involved in such unexpected functional features. 
2.2 The regulation of NK cell function: Activating and inhibitory receptors 
Once NK cells could be physically identified and isolated, the goal was to understand how 
these cells could work; and the first questions were: “How can a single NK cell kill different 
targets?” and “how do NK cells recognize and spare self normal cells?” The answer to these 
questions was indicated by Karre in his “missing self hypothesis”. He postulated that NK 
cells could sense the absence (or reduction) of self MHC class I molecules (MHC-I) during 
cell-to-cell interaction: the missing recognition of self would allow NK cells to kill the 
targets, while recognition of self MHC-I would inhibit their cytolytic activity  (Ljunggren & 
Karre, 1990). This would explain how NK cells could kill tumor or virus infected cells, which 
frequently undergo surface MHC-I down-regulation, and spare self non-pathogenic cells, 
equipped with appropriate levels MHC-I. The hypothesis was then confirmed, and the 
inhibitory MHC-I-specific receptors responsible for the recognition of Self were identified. 
In humans, major HLA-I-specific inhibitory receptors are represented by the C-type lectin 
CD94/NKG2A dimer that recognizes the non-classical HLA-E alleles, and the Killer Ig-like 
Receptors (KIR). The CD94/NKG2A encoding genes are located in the NK Receptor 
complex on chromosome 12, while the KIR locus is located in the Leukocyte Receptor 
Complex in Chromosome 19. The KIRs constitute a family of strictly homologous proteins 
characterized by the presence of two or three extracytoplasmic Ig-like domains (KIR2D or 
KIR3D) and a long cytoplasmic tail (KIR2DL or KIR3DL) containing Immuno Tyrosine-
based Inhibitory Motifs (ITIMs) for the inhibitory signal transduction. Each KIR recognizes a 
specific epitope common to a defined group of HLA-I alleles. In particular, KIR2DL1 
recognizes the Lys80 containing C2 epitope, that is shared by a group of HLA-C alleles; 
KIR2DL2/L3 recognize the Asn80 containing C1 epitope, that is shared by the remaining 
alleles of the locus HLA-C; KIR3DL1 recognizes the Ile/Thr80 containing HLA-Bw4 epitope, 
that is common to certain HLA-A and HLA-B alleles, while KIR3DL2 recognizes certain 
HLA-A alleles (Biassoni et al., 2001; Parham, 2005). Interestingly, KIR3DL2 has also been 
recently shown to bind microbial nucleic acids at the cell surface and to shuttle them to 
TLR9 in the endosome, suggesting for certain KIR a novel (or rather an ancient) function as 
pathogen sensors (Sivori et al., 2010). The HLA-I-specific inhibitory receptors are clonally 
distributed within the NK cell population of each individual. Most NK cells express one or 
more receptors and at least one that recognize an autologous HLA-I allele. Recently, a KIR-
NKG2A- NK cell subset has been described in different donors. These cells, however, 
appeared to be poorly functional. This suggested that the expression and the engagement of 
inhibitory receptors during maturation of NK cells could dictate the acquisition of their 
cytolytic potential (Licensing theory) (Anfossi et al., 2006). The KIR family also includes 
activating KIRs. These are homologous to their inhibitory counterparts, but display a short 
cytoplasmic tail (KIR2DS or KIR3DS), lack ITIMs and associate an ITAM-bearing molecule 
(DAP12) to transduce activating signals. Similarly, also for NKG2A, does exist a short-tailed 
activating counterpart, termed NKG2C. The meaning of these receptors is poorly known. It 
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has been hypothesized that they may recognize HLA-I molecules loaded with viral or tumor 
peptides, or, with low affinity, normal HLA-I molecules. In this latter case, when target cells 
selectively down-regulate HLA alleles, recognized by inhibitory KIR, the engagement of 
activating KIR may result in NK cell activation. The simultaneous expression of activating 
and inhibitory KIRs may therefore represent a strategy whereby NK cells can recognize and 
kill pathologic cells uniquely by detecting changes in their HLA alleles repertoire. At 
present, however, binding to HLA-I molecules has been formally demonstrated only for 
KIR2DS1 and NKG2C. 
NK cells are also equipped with a large array of non-HLA-specific triggering receptors and 
co-receptors, whose engagement by specific Ligands expressed on target cells induces NK 
cell cytotoxicity and cytokine release (Moretta A. et al., 2001; Vivier et al., 2011). The group 
of NK-triggering receptors is largely heterogeneous: it encompasses molecules either 
structurally unrelated or belonging to different molecular families. At variance with KIRs, 
triggering receptors are expressed by virtually all NK cells and, in most cases, by different 
lymphocyte subsets or monocytes. The activating receptor Ligands till now identified, 
appear to be over-expressed in one or more of the following cases: tumor transformation, 
viral infection, cell stress or activation. Consistently, most of the activating receptors have 
been shown to be variably involved in the recognition and killing of virus infected and/or 
tumor cells. Two members of CD2 family: 2B4 (CD244) and NTBA, which recognize CD48 
and NTBA respectively, have been involved in the clearance of EBV-infected cells. NKp80 
and NKG2D, two Killer cell Lectin Receptors (KLR) encoded in the NK gene Complex on 
human chromosome 12, recognize molecules that can be expressed on tumor and/or virus 
infected cells. NKp80 recognizes AICL (encoded in the same NK gene complex) that is 
expressed on activated monocytes, but it can be also expressed on malignant myeloid cells 
(Welte et al., 2006). NKG2D recognizes MHC-I-related stress-inducible molecules of the MIC 
and ULBP families, that can be up-regulated on virus infected or tumor cells. Three 
receptors, that are expressed on cytotoxic lymphocytes (both NK and T cells), DNAM-1 
(CD226), TACTILE (CD96) and CRTAM, recognize members of the Nectin/Nectin-Like 
(NecL) family (Fuchs & Colonna, 2006). In particular DNAM-1, that is the most highly 
espressed on NK cells, recognizes Nectin2 (CD112) and NecL5 (CD155 - poliovirus receptor) 
(Bottino et al., 2003). Nectin/NecL molecules are involved in the formation of various types 
of cell-to-cell junctions, especially in epithelial cells, neurons or fibroblasts. Nectins 1 and 2, 
and NecL5 can also serve as viral entry receptors. These molecules, however, are frequently 
up-regulated in tumor cells of different histotypes. In addition, CMV infection can alter 
NecL5-Nectin3 intercellular interaction: in this case NecL5 would be exposed outside the 
cellular junction and allow DNAM-1 recognition. 
While all the above-mentioned activating receptors are expressed by different leukocyte 
subsets, NKp30, NKp46 and NKp44 triggering receptors are restricted to NK cells. NKp44 
and NKp46 are involved in the recognition of both viral antigens (as the influenza virus HA) 
(Mandelboim et al., 2001) and ligands expressed by tumor cells. NKp30 recognizes B7H6 
and BAT-3 (Brandt et al., 2009; Pogge von Strandmann et al., 2007). B7H6 is a member of the 
B7 family (which includes ligands for stimulatory/inhibitory T cell co-receptors 
CD28/CTLA4). B7H6 is poorly expressed on normal cells, while it is up-regulated in 
different tumor cell lines. BAT-3 is a nuclear factor released in exosomes by tumor cells and 
Dendritic Cells (DC) in response to stress/activation stimuli. The tumor ligands for NKp46 
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and NKp44 remain still undefined. The NKp30, NKp46 and NKp44 receptors are 
structurally and genetically unrelated. NKp46 encoding gene is located within the 
Leukocyte Receptor Complex in Chromosome 19, while the NKp30 and NKp44 encoding 
genes are located in separated regions in chromosome 6. However, for their expression 
pattern, restricted to NK cells, and their impressive capability of triggering NK cell 
cytotoxicity against an extremely wide range of tumor cell lines, they were grouped and 
collectively termed Natural Cytotoxicity Receptors (NCRs). 
Among the triggering receptors, NKp30, NKp46, NKp44, NKG2D and DNAM-1 are 
indispensable for the NK-mediated recognition and killing of tumor cells. Different studies 
have demonstrated how their blockade, impairment of function, or expression failure, 
heavily compromise the efficacy of NK cells in killing tumor cells in vitro, or in containing 
tumor growth in animal models (Bottino et al., 2004; Iguchi-Manaka et al., 2008; Guerra et 
al., 2008; Halfteck et al., 2009). Notably, NK cells can significantly improve their functional 
capabilities in response to various cytokines including type I IFN, IL-2, IL-15, IL-12 and IL-
18. In this context, exposure to IL-2, IL-15 and IL-12 can indeed induce up-regulation of 
NCRs, NKG2D and DNAM-1. In particular major effect is exerted on NKp44 that is not 
expressed at all on resting NK cells (Biron et al., 1999; Moretta A. et al., 2001; Della Chiesa et 
al., 2006; Balsamo et al., 2009; Vivier et al., 2011). 
Thus, NK cells by their inhibitory and activating receptors can sense the altered expression 
of both protective self HLA-I molecules and a large array of pathogenic markers, and on this 
basis can discriminate which cells have to be killed. 
The fact that, at variance with activating receptors, the inhibitory HLA-specific receptors are 
clonally distributed, allows the generation of a repertoire of NK cell subsets capable of 
sensing alteration of even single HLA-alleles. Importantly, this phenomenon is the basis for 
the exploitation of alloreactive NK cell subsets in aplo-identical Hematopoietic Stem Cell 
Transplanation ( HSCT) in hematological malignancies (see section 2.4). 
2.3 Multiple NK cell subsets and functions 
Besides their involvement in direct pathogen clearance, NK cells are also implied in the 
regulation of the immune responses. Indeed they can produce and respond to various 
cytokines, functionally interact with different immune cell types and participate at 
regulation of T cell functions, in particular at Th1/Th2 polarization (Cooper et al., 2001; 
Moretta A. et al., 2005; Scordamaglia et al., 2008). 
Up today several NK cell types, with distinct phenotype, function and anatomical location 
have been described (Table 1).  
The CD56brightCD16dim/negKIR-NKG2A+ NK cells are characterized by low granule content 
and low cytolytic activity but produce large amounts of cytokines, in particular IFN-. These 
cells cover 5-10% of circulating NK cells but represent the large majority of NK cells in 
Lymph Nodes (L.N.). At these sites, upon interaction with maturing DC, CD56bright NK cells 
can proliferate and produce IFN- thus favoring Th1 response (Fehniger et al., 2003; 
Ferlazzo & Munz 2004). 
The classical CD56dimCD16bright NK cells (approx. 90% of circulating NK cells) are highly 
cytotoxic, and also produce cytokines, in particular IFN- and TNF-and, to a lesser extent, 
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chemokines, such as MIP-1. These cells may migrate to peripheral tissues driven by 
chemokines and type I IFNs. Indeed, CD56dimCD16bright NK cells express receptors (CXCR1 
ChemR23 and CX3CR1) specific for chemokines (CXCL8, Chemerin and CX3CL1 
respectively) that are usually produced during inflammatory events by Macrophages, 
Neutrophils, DC and Endothelial cells (Moretta A. et al., 2005; Della Chiesa et al., 2006b; 
Parolini et al., 2007). In addition they also express GPR56, a molecule that would function as 
receptor for Extra Cellular Matrix components (Della Chiesa et al., 2010). In inflamed tissues, 
different viral or bacterial products (i.e. PAMPs - Pathogen Associated Molecular Patterns) 
may either directly activate NK cells (which express TLR6 and TLR9 PAMP receptors) or 
induce DC, plasmacytoid DC (pDC), M1 type Macrophages, to produce cytokines capable of 
activating NK cells. At these sites, CD56dimCD16bright NK cells  can physically interact with 
immature DC (iDC) and, by the engagement of NKp30 and DNAM-1, they can release TNF-
and HMGB1 and promote DC maturation. Once activated, NK cells, by using the same 
receptors (NKp30 and DNAM-1), can also kill iDCs (and spare mature DC - mDC). As 
compared to mDC, iDC express lower HLA-I levels, and are not “protected” from activated 
NK cells. This phenomenon may represent either a mechanism to eliminate those DC that 
have not properly undergone maturation or a signal to terminate the response and avoid 
chronic inflammation (Zitvogel et al., 2002; Moretta A. et al., 2005). 
Recently, a novel CD56+NKp44+ NK cell type was described in MALT (tonsils and Peyer 
patches), and was called NK22, by virtue of its ability to produce IL-22 in response to IL-23 
(Colonna, 2009). IL-22 is a IL-10 family cytokine with anti-bacterial effects, as it maintains 
epithelial-cell barrier function in the gut thus contrasting bacterial dissemination. The 
meaning of NK22 cells, as well as their ontogenesis, are not fully understood, nevertheless 
these cells may play an important role in constraining inflammation and in defense against 
bacterial infection in the mucosa. 
A unique NK cell subset expressing the phenotype CD56brightCD16dim/negKIR+NKG2A+, 
populates decidua in the first trimester of pregnancy (Moffet-King, 2002; Hanna et al., 2006). 
These cells display peculiar functional features: they express the NCRs but are poorly 
cytolytic; rather, the engagement of NKp30 and NKp44 would induce them to produce a 
defined pattern of chemokines and pro-angiogenic factors (see Table 1). These factors would 
favor trophoblast migration and decidua vascularization, ensuring an appropriate placenta 
and fetus development. Decidual NK (dNK) cells may also have a role in the induction of 
tolerance at the maternal/fetal interface. dNK cells, by producing IFN-, would induce 
expression of IDO in decidual myelomonocytic cells. In turn IDO, together with TGF-, 
would favor induction and proliferation of Tregs. Interestingly, unlike PB NK cells (see 
section 2.4), dNK cells are resistant to the inhibition of the IDO-induced Trp-catabolite, L-
kynurenine. This resistance implies that dNK cells can maintain production of IFN- and 
sustain the tolerogenic pathway over time (Vacca et al., 2010). 
It has been recently proposed that the CD56brightCD16dim/negKIR-NKG2A++ cells could 
undergo further differentiation through different stages (Bjorkstrom et al., 2010; Lopez-
Verges et al., 2010). The relatively immature and poorly cytotoxic CD56brightCD16dim/negKIR-
NKG2A++ cells, would progressively increase the expression of cytolytic granules, CD16, 
KIRs and CD57, down-regulate NKG2A, and modify the kinetics of IFN- release. In line 
with this hypothesis, four phenotypically distinct NK cell populations, possibly representing 
sequential stages of this differentiation process, have been identified within circulating pool:  
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CD56brightCD16dim/negCD57-KIR-NKG2A++perforin+/-, CD56dimCD16dimCD57-KIR-
NKG2A++perforin+, CD56dimCD16brightCD57+/-KIR+NKG2A+perforin++, 
CD56dimCD16brightCD57+KIR+NKG2A-perforin+++. 
Interestingly, along these putative differentiation steps NK cells would also progressively 
lose CCR7 and CD62L expression and acquire the fraktalkine receptor CX3CR1, thus 
skewing their initial homing capabilities to L.N., towards inflamed Peripheral Tissues 
(Juelke et al., 2010; Hamann et al., 2011). This latter point should not be disregarded, 
especially in view of the future perspective of selecting appropriate NK cell subsets for 
cancer immunotherapy. 
 
NK cell subpopulation 
(phenotype) 
Anatomical/ 
tissue 
localization 
Functional features 
CD3- 
CD56brightCD16dim/neg
KIR-NKG2A++ 
CCR7++CD62L++ 
CD57- 
 
Lymph Nodes 
5-10% PB NK 
cells 
Differentiation towards KIR+ cells 
Cytokines production (IFN- TNF-) 
mDC-induced prolif. and IFN- prod. (promote 
Th1 polarization) 
CD3-CD56dimCD16bright
KIR+/KIR- 
NKG2A+/NKG2A- 
CCR7-CD62L+/- 
ChemR23+CX3CR3+ 
GPR56+ 
90% PB NK cells
inflamed periph.
tissues? 
Cytotoxicity 
Cytokines production (IFN- TNF-) 
Induction of DC maturation 
CD56-CD161+ 
5-10% PB NK 
cells 
Produce type2 cytokines (IL-5 IL-13) 
Low cytotox. 
Expanded in HIV patients 
CD3-CD56brightCD16dim
KIR+ 
 
Decidua 
(1st. trimester 
pregnancy) 
 
Low cytotox. 
IFN- IL-8++ IP-10+ VEGF+ 
Regulatory interactions with Trophoblasts 
(Placenta development) Decidua vascularization 
Induction of Tregs 
CD3-CD56+NKp44+ MALT IL-22+ / mucosal immunity 
CD3-CD56+CD16+/-
KIR+ 
Liver Cytotoxicity 
Table 1. Surface phenotype, anatomical localization and function of different NK cell subsets 
2.4 Role of NK cells in the control of tumors 
The impressive advances obtained in the last 15-20 years in the knowledge of the 
mechanism of action of NK cells and of their regulation, have been fuelled by the evident 
therapeutic potential that these cells have shown since their first discovery. However, 
although the efficacy of NK cells in containing tumors in vivo has been demonstrated in 
www.intechopen.com
 
Physiological and Pathological Aspects of Human NK Cells 
 
343 
different animal models (Kim et al., 2000; Smyth et al., 2000; Guerra et al., 2008; Halftech et 
al., 2009), the way to develop effective NK-based immunotherapy has been elusive for many 
years and only very recently it yielded promising results. 
After the initial attempts by Rosenberg’s group (Rosenberg et al., 1985), several trials had 
been done to set protocols for the adoptive transfer of ex-vivo activated autologous NK cell 
populations or for the use of different cytokines to elicit NK cell responses in vivo (Sutlu & 
Alici, 2009). The advantages of these approaches, however, appeared minimal: both because 
of the technical limits in expanding ex vivo large bulk populations (as repeated infusions 
were necessary to overcome the short life-span of transferred mature NK cells), and because 
of the putative adverse effects induced by IL-2 in vivo (such as the possible expansion of 
CD25+ Tregs or the induction the AICD) (Ghiringhelli et al., 2005; Rodella et al., 2001). In 
addition, another possible limitation could be that tumor cells could retain sufficient HLA-I 
expression to protect themselves from autologous NK cell attack. A turning point in the 
definition of efficient NK-based immunotherapeutic strategies against cancer, was 
represented by the study by Velardi and co-workers, primarily aimed at the evaluation of 
the clinical outcome of aplo-identical HSCT in Acute Myeloid Leukemia (AML) (Ruggeri et 
al., 2002). In this study the authors suggested that, in the presence of HLA/KIR mismatch 
(i.e. recipient and donor expressing different HLA-I alleles that are recognized by different 
KIRs), NK cells that developed from donor’s progenitors could play an active role in 
reducing both the risk of leukemia relapse and even the Graft versus Host Disease (GvHD). 
This implied that heterologous NK cells could develop in the conditioned host, and kill 
Leukemic blasts more efficiently than autologous NK cells could do. Further studies by 
different groups have led to the current hypothesis that in the host, heterologous NK cell 
population expressing KIRs specific for donor’s and not for recipient’s HLA-I alleles can 
develop and be educated (licensed) by the donor’s bone marrow cells, thus acquiring 
efficient killing capabilities towards host (allogeneic) malignant cells or activated leukocytes 
(Pende et al., 2009; Cooley et al., 2010; Haas et al., 2011; L. Moretta et al., 2011). The 
functional capabilities of allogeneic NK cells would also explain the reduction of GvHD 
observed in patients undergoing HLA/KIR mismatched HSCT, as, besides the elimination 
of heterologous Leukemic blasts (Graft-versus-Leukemia - GvL - effect), donor’s NK cells 
would also be involved in the killing of those host’s DC capable of priming donor’s T cells. 
Interestingly, this alloreactive NK cell population may persist (and exert the its beneficial 
effect) for years (Pende et al., 2009; Haas et al., 2011) without causing apparent detrimental 
clinical signs ascribable to NK cell activity. 
The above studies open new perspectives for the exploitation of NK cells in 
immunotherapy. In this context, different trials have been designed for the treatment of 
hematological malignancies, and in some cases also for solid tumors (Miller et al., 2005; 
Terme et al., 2008; Sutlu & Alici, 2009). Several problems, however, still remain to be solved. 
For example the fact that immature, not fully competent, NK cells may predominate (and 
persist) in circulation during (and after) the recipient immunological reconstitution (Nguyen 
et al., 2005) with negative effects on the anti-tumor activity and surveillance against viruses. 
Another problem regards a general negative effect that malignancies may exert on NK cell 
functions. In this context, different studies have reported a down-regulation of activating 
receptors in circulating NK cells from tumor patients (Sanchez et al., 2010; Le Maux-Chansac 
et al., 2005; Fregni et al., 2011). Moreover , in solid tumors, the tumor microenvironment 
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may play an additional negative role by contrasting both the responses and the infiltration 
capabilities of the immune effector cells (Albertsson et al., 2003). In this context, different 
studies have indicated that in some tumors, infiltrating NK cells may be rare or poorly 
functional (Albertsson et al., 2003; Carrega et al., 2009; Platonova et al., 2011). At the tumor site 
several stromal components, induced by aberrant tumor-driven inflammation, can contribute 
to NK cell down-regulation (Mantovani et al., 2008). Tregs, by the release of TGF-, may 
suppress NK cell functions (Zimmer et al., 2008). The induction of M2 macrophages may 
reduce the macrophage-mediated NK cell activation (as this effect is prominently sustained by 
M1 macrophages) (Bellora et al., 2010). Also the Tumor Associated Fibroblasts (TAF) may 
contrast NK cells in their anti-tumor activity. Indeed, fibroblasts derived from melanoma 
lesions were found to inhibit, by mean of cell-to-cell contact and PGE2 release, the IL-2-driven 
up-regulation of NKp44, DNAM-1 and NKp30 on NK cells (Balsamo et al., 2009). Finally, even 
the tumor cells can induce down-modulation of activating NK receptors. Several tumor cell 
lines constitutively express IDO, an enzyme involved in the Trp catabolism. The IDO-induced 
Trp catabolite Kynurenine has been shown to down-regulate NKp46 and NKG2D (Della 
Chiesa et al., 2006). In addition, tumor cells can also induce down-regulation of NKG2D or 
DNAM-1 on NK cells by the release of soluble NKG2D-Ligands (Doubrovina et al., 2003) or by 
the prolonged engagement of DNAM-1 in cell-to-cell contact (Carlsten et al., 2009) 
3. Human Natural Killer cell development 
3.1 In vitro NK cell development  
3.1.1 Acquisition of NK cell receptors and function  
Most of information available on human NK cell development came from in vitro studies of 
NK cell differentiation from CD34+ Hematopoietic Stem Cells (HSC) or CD34+/-CD45RA+ 
early lymphoid precursors. These cells can be isolated from different sources such as fetal 
liver, Bone Marrow (BM), Thymus, PB and Umbilical Cord Blood (UCB) and stimulated 
with IL-2 or IL-15, in the presence or in the absence of feeder cells,  to obtain NK cell 
differentiation (Freud & Caligiuri , 2006). In the 90s’ it was shown that it was possible to 
obtain CD3-CD56+ CD94/NKG2A+ cytolytic NK cells from either CD34-CD45RA+CD7+CD1a- 
early thymic precursors (Mingari et al., a1991,b1997; Lanier et al., 1992; Sanchez et al., 1994) 
or CD34+HSC isolated from BM or UCB (Miller et al., 1994; Lotzova et al., 1993).  
Currently, optimal culturing conditions require the simultaneous presence of different 
cytokines: Stem Cell Factor (SCF), FMS-Like Tyrosine Kynase Ligand (Flt3-L), IL-7, IL-15 
and IL-21.  
During in vitro differentiation the development of NK cells proceeds through a step-by-step 
process (figure 1) (Freud& Caligiuri, 2006). Freshly isolated HSC precursors already express 
CD117 and Flt3, which are the SCF and Flt3-L receptors, respectively, and play an important 
role for their proliferation and survival before any cell lineage commitment takes place . The 
first cell markers that would suggest a NK-lymphoid commitment are the IL-2/IL-15 
receptors CD122, CD132 and the IL-7 -chain receptor (CD127). These receptors play an 
important role in transducing proliferation and differentiation signals upon interaction with 
the appropriate cytokines (IL-15 and IL-7 respectively). However, in humans, these markers 
are rarely detectable on ex-vivo isolated CD34+CD45RA+ precursors, while  they can be 
detected on small fractions of precursor after first days of culture (Freud& Caligiuri, 2006).   
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The first surface cell marker that clearly identify NK cell precursors is CD161 (Bennet et al., 
1996). It can be detected on small percentages of CD3-CD56-CD117+cells, which already 
express CD244 co-receptor: the acquisition of NKp44 activating receptor and CD56 
represents the following differentiation step. Next, the expression of the NKp46, NKG2D 
and DNAM-1 activating receptors and of CD94/NKG2A inhibitory receptor occurs. The 
acquisition of CD16 and KIRs can be hardly observed in vitro (Mingari et al., 1997; Miller et 
al., 2001; Sivori et al., 2002). These receptors are typical of functionally differentiated 
circulating NK cells: their acquisition by small percentages of cell precursors undergoing 
differentiation, appears after long term cultures in the presence of IL-21, a pro-inflammatory 
cytokine (Sivori et al., 2003). On the other hand, the early expression of NKp44 may be 
related to the fact that recombinant IL-15, present in the culture, rapidly activates NKp44 
gene transcription. Hence, NKp44 transcription could be differently regulated from that of 
the other activating receptors.  
This sequential process of cell marker acquisition identifies NK cell precursor intermediates 
with different functional properties (Freud & Caligiuri, 2006; Grzywacz et al., 2006). Early 
NK cell precursors CD117+CD161+CD244+CD56+/- NKp44+/- are not cytolytic but can secrete 
cytokines such as GM-CSF and IL-13. These cells lack the expression of all the other 
activating receptors and inhibitory receptors. The next stage of in vitro NK cell 
differentiation correlates with the definitive acquisition of CD56 and of NKp44 
(CD117+CD161+ CD244+CD56+NKp44+): these precursors can be defined as immature NK 
cells (iNK). Immature NK cells secrete large amounts of CXCL8 and low amounts of IL-22 
while they do not produce IFN-Freud & Caligiuri, 2006;Vitale et al., 2008; Tang et al., 
2011). The production of CXCL8 could have a role in the modulation of hematopoietic cell 
lineage commitment. In particular, CXCL8 inhibits myelopoiesis (Youn et al., 2000) and, 
thus, might favour NK cell differentiation. On the other hand, iNK cells are not cytotoxic. 
Indeed they have not acquired yet cytolytic granules in their cytoplasm, important NK 
activating receptors (i.e. NKp46), and the adhesion molecule LFA-1, that strongly contribute 
to the activation of cytolytic machinery (Bryceson et al., 2006).  
The acquisition of a weak cytolytic activity correlates with the expression of NKp46 
activating receptor and LFA-1; however, at this stage of development, the NKp46-mediated 
cytotoxicity against susceptible cell targets may be inhibited by the CD244 co-receptor, that 
acts as inhibitory receptor on these iNK cells. CD244 works as an activating co-receptor on 
mature NK cells thanks to the recruitment of an intra-cytoplasmic adaptor molecule SAP. 
However, on CD117+/-CD161+ CD244+CD56+NKp46+/-CD94/NKG2A-LFA-1+/- iNK cells 
SAP it is not synthetized yet, leading to inhibitory rather than activating function of CD244 
(Moretta et al., 2001; Sivori et al., a2002, b2003; Vitale et al., 2008). 
The full acquisition of cell functions typical of mature NK cells, such as IFN- secretion and 
cytolytic activity, correlates with the surface bright expression of NKp46, the expression of 
NKG2D and DNAM-1 activating receptors, CD94/NKG2A inhibitory receptor and of LFA-1 
molecule. At this stage, SAP starts to be synthesized, and CD244 acquires a co-stimulatory 
activity. These cells are defined as CD56bright NK cells since they are very similar to CD56bright 
CD94/NKG2A+CD16-KIR- NK cells present in the PB. Notably, differentiation is a 
continuous process and cells may not be synchronized in their maturation status: hence, a 
certain heterogeneity of the different cell subsets may be observed.  
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Altogether these experimental evidences indicate that NK cell development is tightly 
regulated and that evolution had particularly tuned the acquisition of cytolytic activity. NK 
cells, to become cytotoxic, must express at least the NKp46 activating receptor and the LFA-
1 adhesion molecule. Simultaneously, they have to loose the inhibitory activity of CD244 co-
receptor. The ability to control NK cytotoxicity by inhibitory CD244 could be a “safe” 
mechanism, important in the interactions between NK cell precursors and other 
hematopoietic cells. CD244 ligand is the CD48 molecule, which is expressed by different 
types of leucocytes and hematopoietic precursors (Cannons et al., 2011). On the other hand, 
iNK cells secrete a peculiar pattern of cytokines, such as IL-22 and CXCL8, involved in 
inflammatory process, defence against bacteria, neo-angiogenesis and modulation of 
haematopoiesis. Hence, iNK cells might exert important crosstalk with other cells present in 
microenvironment where their differentiation takes place.  
3.2 Factors that modulate NK cell differentiation 
Hematopoietic cell lineage commitment depends on a wide variety of factors. Genetic 
components dictate the initial commitment but the milieu that surrounds lineage precursors 
may have a key role in the fate of these cells. The balance between specific transcription 
factors and the appropriate cytokines and hormones can change the commitment of 
intermediate lymphoid precursors, inducing their switch towards alternative lineages 
(Laiosa et al., 2006; Doulatov et al., 2010). In this context, in vitro analysis have shown that 
NK cells can share intermediate precursors not only among lymphoid cells but also with 
dendritic cells and myeloid cells (Miller et al., 1999; Marquez et al., 1998; Perez et al., 2003; 
Vitale et al., 2008; Grzywacz et al., 2011). 
3.2.1 Cytokines 
Cytokines are important factors that modulate NK cell differentiation. SCF and Flt3-L have a 
role in the first days of in vitro development because they induce HSC to enter into the cell 
cycle, and sustain precursor proliferation and survival (Yu et al., 1998). Then, IL-7 supports 
the lymphoid lineage commitment, since this cytokine is involved in T cell homeostasis and 
lymphoid differentiation (Ma A. et al., 2006). However, it is IL-15 that plays a key role in NK 
cell differentiation, through the interaction with IL-2/IL-15 common  and  chains 
receptors (CD122 and CD132, respectively). Indeed, IL-15 has been shown to be critical in 
the terminal differentiation of CD117+/-CD161+CD56+ iNK towards mature NK cells 
(Mrozek et al., 1995; Freud & Caligiuri, 2006). In murine models, NK cell deficiencies are 
more pronounced in mice lacking IL-15 or its receptors, than in mice lacking IL-2 or IL-7 
related products (Di Santo et al., 1990; Giliani et al., 2005; Kennedy et al., 2000). In vitro 
assays revealed that high dose soluble IL-15 binds to its receptors and promote NK cell 
differentiation but, in vivo, IL-15 is primarily detectable complexed to its IL-15 Receptor 
(IL15-R) present on accessory (stromal) cells (Dubois et al., 2002). IL-15/IL15-R complex 
would then present the cytokine in trans to CD122+CD132+ cells, meaning that also stromal 
cells could exert an important role in the terminal differentiation of iNK cells (Miller et al., 
1994; Briard et al., 2002; Vacca et al., 2011). Finally, IL-21 have been shown to increase the 
proportions of CD56+KIR+ cells undergoing in vitro differentiation (Sivori et al., 2003).  
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3.2.2 Transcription factors 
In vitro and in vivo studies using mice with loss-of-function mutation helped to clarify the 
role of many transcription factors (TFs) involved in NK cell commitment, proliferation and 
maturation. Some of them, like the E proteins, orchestrate a lymphoid-biased cellular 
context versus myeloid compartment (de Pooter et al., 2010) but must be down-regulated to 
allow NK cell differentiation (Boos et al., 2007). Other TFs are important both in the NK cell 
and T cell commitment, such as Notch-1 or Id2 (Benne et al., 2009; Boos et al., 2007). Id2 is an 
helix loop helix TF, able to modulate the activation the E protein E2A, and have been shown 
to exert a prominent role in NK cell commitment. Recently, other two TF have been suggested 
to induce definitive early NK cell commitment:  a High Mobility Group protein, called TOX, 
and a basic leucin zipper, E4PB4 (also known as NFIL3)(Aliahmad et al., 2010; Gascoyne et al., 
2009; Kamizono et al., 2009). It has been shown that IL-15 activates E4PB4 that, in turn, would 
activate Id2 transcription, leading to a definitive NK cell commitment and expansion of NK 
cell precursors. In humans, E4BP4 and Id2 expression can be observed either in ex-vivo-
isolated early committed CD34+/-CD122+CD127+ NK cell precursors either in in vitro-derived 
CD117+/-CD161+CD56+LFA-1-NKG2A- iNK cells (Hughes et al., 2010; Vacca at al., 2011). On 
the other hand, TOX would influence the activation of T-bet,  a TF that correlates with the 
acquisition of cytolytic activity and the ability to produce IFN- by more differentiated 
CD161+CD56+LFA-1+ NKp46+ CD94/NKG2A+ NK cells (Yun et al., 2011).  
Expression of others TFs appears to correlate with the different stages of NK cell 
differentiation. RORC correlates with the secretion of IL-22 by iNK cells (Tang et al., 2011) 
while the expression of EOMES (a T-box TF), similar to T-bet, correlates with IFN- 
production by more differentiated NK cells (Glimcher et al., 2004). 
3.2.3 Corticosteroids 
In the last years the studies on in vitro NK cell development offered new important clues on 
NK cell lineage commitment and on the factors that may modulate this process. 
The attempt to improve models of in vitro NK cell differentiation, induced many groups to 
test additional factors, besides cytokines, that could favour in vitro NK cell differentiation: 
in particular, stromal cells and/or corticosteroids. These new protocols revealed an 
unexpected function for glucocorticoids, which were already known to exert a modulatory 
effect on T cell development (Jondal et al., 2004). Studies with Hydrocortisone (HC) showed 
that it was possible to obtain NK cells from the in vitro culture of CD33+CD14+/- myeloid 
progenitors isolated from UCB (Perez et al., 2003). These results suggested that, in cord 
blood, it was possible to switch the differentiation of monocyte precursors towards NK cells. 
We obtained similar results with Methylprednisolone (MePDN). This corticosteroid is 
commonly used as first line of treatment for acute GvHD after allogeneic HSCT. Our 
hypothesis was that MePDN could inhibit not only mature NK cell proliferation and 
functions but also the in vitro NK cell differentiation. Surprisingly, our results showed that 
pharmacological concentrations of MePDN accelerated NK cell differentiation and were able 
to induce myeloid precursors to switch their differentiation towards CD161+CD56+NKp44+ 
iNK cells (Vitale et al., 2008). More recently, Grwaycz et al., with an elegant in vitro 
experiment, provided evidence that HC, in combination with a stromal cell line, induce 
differentiation of CD33+CD13+CD115+/- myelomonocytic precursors into cytolytic 
CD56+NKp46+CD94/NKG2A+KIR+/-CD16+/- NK cells (Grwaycz et al., 2011). 
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These results offer important clues to better clarify some major issues that have been 
discussed in the last years.  
The first one is related to the hematopoietic cell lineage commitment. Current models of 
haematopoiesis suggest that HSC may commit early to the erythroid/platelet lineages or to 
leukocyte lineages. However, once committed to the leukocyte lineage, hematopoietic 
precursors would retain a high plasticity. Thus, the choice to terminally differentiate 
towards myeloid or lymphoid lineages would then depend on the role of lineage-specific 
transcription factors and on a permissive milieu (Doulatov et al., 2010). This would be of 
particular interest for NK cells, which are the only lymphocytes assigned to natural 
immunity compartment and that appear to be the connection ring with acquired immunity.  
The second issue regards the role of NK cells after HSCT and their use in immunotherapy to 
obtain GvL reaction. The possibility that myeloid precursors, in the presence of 
corticosteroids, could generate more rapidly functional NK cells offers important clues also 
in the clinical settings (Vitale et al., 2008; Grwaycz et al., 2011). It is conceivable that NK  
 
Fig. 1. Acquisition kinetic of receptors and  functions by NK cells undergoing in vitro cell 
development. 
Three main precursor subsets may be identified along different time intervals of culture: 
NK cell precursors, immature NK cells and more differentiated CD56bright NK cells. The 
appearance of CD56dim CD16+KIR+ NK cells (red cell) is a late and rare event and is more 
achievable in the presence of IL-21. Stages of differentiation are endowed with a peculiar 
surface phenotype and functions. In particular the acquisition of cytolytic activity correlates 
with the expression of LFA-1, activating receptors and the production of IFN-while high 
secretion of IL-8 correlates with the immature NK cell stage. 
www.intechopen.com
 
Physiological and Pathological Aspects of Human NK Cells 
 
349 
cells, present in high percentages in peripheral blood of patients at the earliest time intervals 
after HCST, may derive, at least in part, from myeloid precursors. Importantly, this 
maturation could not occur wholly in BM but also in PB and other sites. This is the third 
important issue that have been matter of debate of the last years: the site of in vivo human 
NK cell development and maturation. 
3.3 In vivo NK cell development and maturation 
NK cells were generally believed to differentiate into the BM from CD34+ hematopoietic 
stem cells (Freud & Caligiuri, 2006). However, NK cell developmental intermediates were 
detectable in vivo neither in the BM nor in thymus. The possibility to observe in vivo any 
different NK cell developmental stages detectable in vitro, came from analysis of 
lymphocyte recovery in patients undergoing allogeneic HSCT. Analysis of PB of these 
patients revealed that,  in some of them, the first waves of lymphocytes recovering at early 
time after transplant (2-3 weeks) are mostly NK cells. These lymphocytes are characterized 
by the CD56bright CD16- CD94/NKG2A+KIR- phenotype and a dull expression of NCRs, 
while CD56dimCD16+CD94/NKG2A+KIR+ NK cells can be detected later, (4-8 weeks after 
transplant). (Vitale et al., 2000; Shilling et al., 2003; Vitale et al., 2004).  
3.3.1 Sites of in vivo NK cell development: Stages of NK cell differentiation 
The finding that in vitro models of NK cell differentiation led to the generation of CD56bright 
CD16- NK cells, supported the hypothesis that, in vivo, this subset could be a precursor 
reservoir, able to promptly differentiate towards more cytotoxic CD56dimCD16+ upon 
specific stimuli. However, experimental evidences that support this hypothesis have been 
acquired only recently. Freud and co-workers discovered that CD45RA+CD117- and 
CD34+CD45+CD117+CD161+/- cells were enriched in Secondary Lymphoid Tissue (SLT), 
particularly in lymphnodes and tonsils. Importantly, these precursors were able to generate 
selectively NK cells upon culture in the presence of appropriate cytokines. They defined 
these cells as pro-NK and pre-NK cells respectively. Further analysis revealed that in SLT, it 
was possible to detect and isolate four different subsets of NK cell precursors representing 
different stages of NK cell differentiation (Freud et al., a2005, b2006).  
Stage 1: CD34+CD45RA+CD117-CD161- pro-NK cells; stage 2: 
CD34+CD45RA+CD117+CD161+/- pre-NK cells; stage 3: CD34-CD117+CD161+CD56+/-
NKp46-CD94/NKG2A-KIR-CD16- immature NK cells; stage 4: CD117+/- 
CD161+CD56+NKp46+CD94/NKG2A+KIR+/-CD16-, defined as CD56bright NK cells. Further 
analysis suggested that also the expression of CD122 and CD127 could help to identify 
stage 1/2 of pre-NK cell precursors. These discoveries confirmed for the first time that in 
vitro models of NK cell differentiation may have in vivo similar counterpart. Indeed, the  
above stages 2, 3 and 4  remind the differentiation steps observed in vitro (Freud & 
Caligiuri et al., 2006; Caligiuri, 2008). This discovery suggests that hematopoietic 
precursors could migrate from BM to SLT and generate NK cells in organs far from the 
BM. It is possible that at least a fraction of CD56bright NK cells present in SLT could 
differentiate from these precursors upon interaction with DC and other cells capable of 
presenting membrane-bound IL-15.  
As mentioned above a particular subset of NK cells has been found to be enriched in tonsils 
and gut-mucosa associated tissue: these cells are CD56+/-NKp46+/-NKp44+NKG2A- and 
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produce IL-22. Their development appears to be independent from IL-15. However, whether 
these cells may represent a new subset of NK cells (called NK22 cells) or simply immature 
NK cells with peculiar in vivo functions is still a matter of debate (Colonna, 2009).  
In conclusion, BM microenvironment may provide a fundamental support for the early 
stages of NK cell differentiation but peripheral tissues, in particular SLT, could provide a 
unique cell-to-cell interactions and cytokines to induce the terminal NK cell differentiation. 
 
Surface 
markers 
STAGE 1: 
Pro-NK 
STAGE 2: 
Pre-NK 
STAGE 3: 
iNK 
STAGE 4: 
CD56 bright 
STAGE 5: 
CD56dim 
CD16+ 
CD34 + + - - - 
CD45RA +/- +/- (+)/- +/(-) +/(-) 
CD117 - + + +/- - 
CD122 - - - +/- + 
CD127 dull dull + +/- - 
CD161 - +/- + + + 
CD244 + + + + + 
CD56 - (+)/- +/- + + 
NKp44 - - +/(-) (+)/- (+)/- 
NKp46 - - - + + 
NKG2A - - - + +/- 
KIR - - - (+)/- +/- 
CD16 - - - - - 
Table 2. Expression of surface markers by NK cell precursor intermediates isolated in SLT, 
according to model proposed by Freud and co. Legend: +/- variable expression; (+)/- 
majority of cells negative; +/(-) majority of cells positive; dull= weak expression 
3.3.2 Other sites of in vivo NK cell development 
The next step was to verify the possibility that NK-committed cell precursors could be 
isolated in other peripheral tissues, where peculiar NK cell subsets were enriched. Indeed 
NK–committed precursors were found in gut, endometrium and placenta (Chinen at al., 
2007; Male et al., 2010; Vacca et al., 2011). In all these districts there is a high concentration of 
CD56bright NK cells characterized by immune-regulatory activity. In particular, NK cells 
present in human decidua (dNK) during the first trimester of pregnancy display a peculiar 
phenotype (CD56brightCD16-NKG2A+KIR-/+) and exert peculiar functions. For long time dNK 
cells were supposed to derive from PB NK cells undergone phenotypic and functional 
modifications upon interaction with decidual microenvironment. Recently, different 
experimental evidences suggested that dNK cells could derive from NK precursors already 
present in endometrium or in decidua, able to promptly differentiate upon stimuli given by 
the onset of pregnancy (Male et al., 2010; Vacca et al., 2011). In particular, it has been shown 
that NK cell lineage-committed CD34+CD127+CD122+ cells expressing E4BP4 and Id2 TFs 
are present in human decidua (dCD34+) during the first trimester of pregnancy. They can 
undergo in vitro differentiation into functional CD56brightCD16- NK cells in the presence of 
suitable cytokines. More importantly, they could also differentiate without exogenous 
cytokines when co-cultured with decidual stromal cells (dSC), able to express endogenous 
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membrane-bound IL-15. These results suggest that interaction between CD34+ cell and 
decidual stromal cells would be sufficient to promote in situ NK cell differentiation. 
3.3.3 The stage five of human NK cell differentiation: CD56
dim
 CD16
+
CD94/NKG2A
+/-
KIR
+
 NK cells 
As already discussed, several evidences suggest that CD56dim NK cells may derive from 
CD56bright NK cells. After HSCT the first wave of NK cells is represented by 
CD56brightCD16CD94/NKG2A+KIR- cells while CD56dimCD16+CD94/NKG2A+/-KIR+ cells 
appear later. Importantly, CD56bright display longer telomeres than CD56dim NK cells. 
Moreover, different phenotypically defined NK cell subsets have been recently proposed as 
functional intermediates between the CD56bright and CD56dim cell types (see section 2.3) 
(Romagnani et al., 2007; Juelke et al., 2010).  
However, in in vitro assay, it is almost impossible to observe significant expansions of KIR+ NK 
cells from any type CD34+ cell precursors. Similar problems must be related to our inability to 
fully recreate the in vivo milieu in in vitro assay. CD56dim may acquire their surface phenotype 
and functional properties upon peripheral tissues/blood microenvironment stimuli. However, 
signals that drive the differentiation of CD56dim NK cells, both during normal homeostasis and 
infections, remain still elusive. Recent studies provided evidence that CD56dim cells change their 
phenotypic properties and continue to differentiate throughout their lifespan. The loss of 
expression of NKG2A, the acquisition of KIRs and CD57 would allow the identification of 
sequential steps of cell maturation accompanied by a progressive decline of cell proliferation 
and of responsiveness to cytokine stimulation. In particular, CD16 and KIR would be acquired 
at late stages of peripheral blood NK cell maturation (Björkström et al., 2010; Lopez-Vergès et 
al., 2010). Since the acquisition of KIR repertoire in each single NK cell is a stochastic process, 
related to the KIR genotype and polymorphism, it is important to understand how NK cells 
may be educated to avoid auto-reactivity. They should acquire appropriate KIR able to prevent 
them from killing healthy self-cells. However, in PB of normal donors, it is possible to detect 
NK cells expressing KIR mismatched for self HLA-I ligands or not expressing any HLA-I 
inhibitory receptor at all. These cells could represent a danger as they would not recognize self 
HLA-I on self normal cells. As above mentioned, however, it has been recently proposed that 
during their development only those NK cells expressing inhibitory receptors specific for self 
HLA-I ligands would acquire full functional competence, while cells that fail to express such 
receptors (i.e. potentially autoreactive NK cells) would retain a state of hypo-responsiveness. It 
has to be noted, however, that the question on how such licensing/educational process could 
actually occur in vivo is still matter of debate (Parham, 2006; Vivier et al., 2011).  
The interest for NK cells and their clinical application for the control of leukemic relapse 
after allogeneic HSCT is enormously increased in the last years: hence, it is mandatory 
trying to clarify the epigenetic factors that regulate KIR acquisition and functions, because 
their expression pattern on allogeneic donor NK cells play a crucial role in the eradication of 
recipient’s leukemia (Moretta et al., 2011). 
4. Classification of NK cell disorders 
The World Health Organization (WHO) classification of tumors of hematopoietic and 
lymphoid  tissues encompasses four distinct entities, two of which are provisional: 1) NK 
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cell lymphoblastic leukemia/lymphoma (provisional) (Borowitz  et al., 2008); 2) Chronic 
Lymphoproliferative Disorder of NK cells (provisional) (Villamor et al., 2008); 3) Aggressive 
NK cell leukemia (Chan et al., 2008a);  and 4) Extranodal NK/T-cell lymphoma, nasal type 
(Chan et al., 2008b). In addition, on the basis of morphology, immuno-phenotype, functional 
NK cell activity, and expression of cytotoxic molecules, NK cell neoplasms can be divided 
into immature and mature categories (Jaffe, 1996).  
In recent years rare cases of lymphoblastic lymphomas/leukemia arising from immature 
NK cells has been reported, although the lack of suitable markers for immature NK cells 
mentioned above makes it difficult to distinguish NK-cell lymphoblastic lymphoma (LBL) 
from precursor T-cell LBL. It is also worth mentioning that the plasticity of hematopoietic-
cell lineage seems greater than previously thought, and relations between phenotypically 
dissimilar neoplastic disorders are being reassessed. In contrast, it is believed that chronic 
lymphoproliferative disorder of NK cells, aggressive NK cell leukemia and extranodal NK 
cell lymphoma, nasal type, originate from mature NK cells (Chan et al., 2008a and b). 
Relevant biological features of NK cell neoplasms are summarized in Table 3. 
 
 
 
NK cell 
lymphoblastic 
leukemia/ 
lymphoma 
Extranodal NK/T-
cell lymphoma, 
nasal type 
Aggressive NK cell 
leukemia 
Chronic 
Lymphoproliferative 
Disorder of NK cells 
 
Age 
 
Pediatric Middle-aged adult
Young to Middle 
aged adult 
Adults (6th decade) 
Geographic 
distribution 
Worldwide Asia Asia Worldwide 
Cell 
origin 
Immature NK 
cell 
Mature NK cell Mature NK cell Mature NK cell 
Relevant 
phenotype 
sCD3-CD4-CD13-
CD33- CD16-
CD7+ 
CD2+CD56+CD3
e+ 
 
CD2+sCD3-
cCD3e+CD56+CD1
6- CD57- 
Granzyme B+ 
Perforin+TIA1+ 
sCD3-
cCD3e+CD56+CD
16+ CD57-, CD94+
CD3-
CD8+CD16+CD56+C
D57+ 
KIRs+CD94/NKG2A+ 
Granzyme 
B+Perforin+ 
Relevant 
cytogenetic 
aberrations 
Complex 
karyotype 
Deletion 6q 
Deletion 6q 
Complex 
Karyotype 
Usually Normal 
Karyotype 
EBV 
association 
No Yes Yes No 
Clinical 
course 
Aggressive Aggressive Very Aggressive Indolent 
Prognosis Poor Poor Poor Good 
Table 3. Clinical and Biological features of NK cell neoplasms 
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4.1 Immature NK cell neoplasms  
4.1.1 NK cell lymphoblastic leukemia/lymphoma, provisional 
A considerable confusion has been generated in the literature concerning this type of 
disorder, mostly due to the definition of NK cell leukemia on the basis of expression of 
CD56 antigen. This is indeed the most important and sensitive NK marker; unfortunately, 
CD56 is not specific for NK cells and can be also expressed in AML and ALL and blastic 
plasmacytoid dendritic cell neoplasms (BPDCN). On the other hand it may not be expressed 
by immature NK cells. NK cell lymphoblastic leukemia/lymphoma can be considered in 
cases showing blastic morphology, expressing CD56, TdT, immature T associated markers 
such as CD7 and CD2, and cytoplasmic CD3, but lacking the expression of surface CD3, 
CD19, CD20, CD13, CD33, and MPO (Liang & Graam, 2008). These patients frequently 
presented with leukemia and lymphadenopathy without skin involvement and were 
negative for EBV. TCR and/or Ig genes were in germline configuration in all cases in which 
the tests were performed. Outcomes of these patients were absolutely unfavourable. The 
immature morphology with NK cell-associated phenotype and genotype suggests that these 
tumours represent the true precursor NK cell neoplasms.  
Some well characterized cases of NK precursor tumours with lymphomatous presentation 
that expressed CD94 1A transcripts have been reported (Lin et al., 2005). CD94 1A, a distal 
promoter of the CD94 molecule, is activated only by IL-15 (Lopez-Botet et al., 1997). Lin et 
al., recently reported that CD94 1A is the predominant form found in immature NK cells 
and it is expressed in TCR- lymphoblastic leukemia (NK lineage LBL) but not in TCR+ LBL 
(T lineage LBL) (Lin et al., 2005). By studying 21 patients with LBL and, on the basis of the 
expression of CD94 1A transcripts and the lack of TCR, the above investigators identified 7 
patients with LBL of immature NK cell origin (CD94 1A+, TCR-). It is noteworthy that those 
NK-LBLs occurred in young patients and had better outcomes as compared with patients 
who had T-LBL (CD94 1A-, TCR+); none of the tumours was positive for CD56 (Lin et al., 
2005). Thus, the use of CD94 1A associated with TCR appears to be more suitable than CD56 
for identifying an immature NK cell neoplasm. 
A standard treatment protocol for immature NK cell neoplasms has not been established 
mainly because of the rarity of these cases. Current chemotherapy strategies for non-
Hodgkin’s lymphoma or acute lymphoblastic leukemia (ALL) were the most commonly 
used. However, the overall outcomes were dismal and HSCT  represents the only effective 
therapy to achieve a complete remission  (Lin et al., 2005).  
4.2 Mature NK cell neoplasms 
4.2.1 Extranodal NK/T cell lymphoma, nasal type 
The WHO classification encompasses both nasal NK/T cell lymphoma and extra-nasal 
NK/T cell lymphoma in the same category (Chan et al., 2008a). They share the same 
histology, even though these lymphomas may have different clinical manifestations, 
treatment approaches, and prognoses (Oshimi, 2007). Although most cases are genuine NK 
cell neoplasms, the term “NK/T” rather than “NK” is used because this entity also includes 
cytotoxic T cell neoplasms (Sozumiya et al., 1994). Nasal and extra-nasal NK/T cell 
lymphoma are invariably associated with EBV and have a ethnic predisposition, being more 
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prevalent in Asia, Mexico, and Central and South America (Chan et al., 2008b; Kwong, 2005) 
and rare in Western Countries, the Middle East and Africa. 
Nasal NK/T cell lymphomas refer to tumours that occur in the nose and the upper aero 
digestive tract (Oshimi, 2007; Cheung et al., 1998). They are the most common type among 
primary lymphomas of the nasal cavity (Cheung et al., 1998). The site of disease is primarily 
in the midline and includes the nasal cavity in more than 80% of cases. The tumour is locally 
invasive and might infiltrate surrounding tissues and organs, such as oropharynx, palate, 
orbits, till the appearance of the characteristic mid-facial destructive lesions, the so called 
“lethal midline granuloma” (Cheung et al., 1998). Common symptoms include nasal 
discharge, nasal obstruction, purulent rhinorrhea, epitasis and local swelling of the nasal 
bridge. The tumours may be destructive, leading to the highly characteristic midline 
perforation.  
Extra-nasal NK/T cell lymphomas represent the counterpart of nasal NK/T cell lymphomas 
and involve any other part of the body. Males are predominantly affected, and the median 
age of presentation is the fifth decade. Primary sites of involvement include the skin, 
gastrointestinal tract, salivary glands, spleen, and testis (Chan et al., 1997). Patients with 
extra-nasal NK/T cell lymphoma more likely exhibit an advanced stage of disease with 
significantly higher general involvement, high levels of lactate dehydrogenise and a 
significantly decrease of haemoglobin and platelet count as compared with patients who 
have nasal NK/T cell lymphoma (Chan et al., 1997). The histological features are similar, 
regardless of the involved sites. Mucosal sites often show ulceration. A diffuse infiltrate of 
lymphoid cells is found in association with tissue necrosis and coagulation, although in 
some cases infiltrating cells lack atypical morphology, resulting in misdiagnosis as chronic 
inflammation. An angiocentric and angiodestructive growth pattern with associated 
fibrinoid changes in the blood vessels is frequently observed. In most patients, the 
neoplastic cells are characterized by the CD45+ surface (s)CD3- cytoplasm (c)CD3ε+ CD56+ 
phenotype and lack myeloid and B lymphoid markers. Proliferating cells are also positive 
for cytotoxic granules, granzyme B, perforin, TIA. Rarely cells express CD30 and CD7, while 
CD56 negative cases have also been reported. Association with EBV can be demonstrated in 
nearly all patients (Harabuchi et al., 1990). Using in situ hybridization technique, EBV-
encoded RNA can be found in neoplastic cells and Southern Blot analysis can detect 
monoclonal proliferation of EBV. Analyses of the terminal repeat region of the EBV genome 
indicates that the virus is in a clonal episomal form. Other than providing an indirect proof 
of the clonal nature of the lymphoid proliferation, this finding suggests that the EBV might 
play an etiologic role in mature NK cell neoplasms (Minarovitz, 1994). A defect in immune 
surveillance for EBV infection is demonstrated by the high frequency of 30-base pair 
deletions of the LMP1 gene in EBV-infected Asians. In addition, amino acid changes in the 
sequence coding HLA-A2- restricted CTL epitopes of the LMP1 and LMP2 genes, and low 
frequency of HLA-A*0201 in NK/T cell lymphoma patients have been reported (Kanno et 
al., 2000;  Harabuchi et al., 2009). Genetic alterations have been detected in the tumour 
suppression genes and several oncogenes enabling tumour cells to proliferate and resist 
apoptosis. Mutations of p53 have been demonstrated, with variable frequencies (24 to 60%). 
Mutation of c-kit can also be frequently demonstrated, as far as Fas gene mutations (Hoshida 
et al., 2003; Shen et al., 2002). The most common cytogenetic aberration is deletion of 6q. A 
recent microarray study showed that several genes associated with vascular biology, EBV 
induced genes, and PDGFRa gene are over-expressed, pointing to the deregulation of the 
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tumor suppressor HACE1 in the frequently deleted 6q21 region (Huang et al., 2010). 
Moreover, in NK/T cell lymphoma, gene signatures related to angiogenesis, genotoxic stress 
and proliferation, and signaling pathways (TGF-, Notch and Wnt), were significantly 
enriched as compared to IL2-activated normal NK cells. Interestingly, NK/T lymphoma 
cells of NK lineage have a very similar molecular profile to that of NK/T-cell or peripheral 
T-cell lymphoma of -T cell lineage (Iqbal et al., 2010). 
The clinical outcome of patients with nasal NK cell lymphoma is variable. Most 
observational studies have consistently demonstrated that radiotherapy is superior to 
chemotherapy alone in patients with stage I/II disease (Sakata et al., 1997). Some patients 
with early-stage disease are cured by radiation therapy. It has been demonstrated that 
radiotherapy, either as initial treatment or as part of the chemotherapy regimen, is the single 
most important key to a successful outcome (Ribrag et al., 2001). However, some patients 
with early-stage disease have early local or systemic recurrences and die of disease. For 
patients with stage III/IV disease, chemotherapy is the treatment of choice (Kwong, 2005). 
In several published series, the median survival of patients with advanced-stage disease was 
approximately 12 months. Extra-nasal NK cell lymphomas are clinically aggressive, the 
response to therapy is poor, and most patients die within 6 months after diagnosis. The 
long-term remission rate with allogeneic HSCT is less than 10% (Cheung et al., 1998).  
4.2.2 Aggressive NK cell leukemia 
First described by Fernandez et al., (Fernandez et al., 1986), aggressive NK cell leukemia  
(ANKL) is a systemic disease, more common in Asians than in Caucasians (Chan et al., 2008a), 
which is characterized by the presence of neoplastic NK cells in the peripheral blood, bone 
marrow, liver and spleen and by a rapidly progressive clinical course with poor prognosis. 
There is an equal sex incidence in men and women. The disease typically affects young to 
middle-aged adults with a median age in the third decade. At presentation, patients usually 
are very compromised with systemic symptoms, liver dysfunction, and hepato-splenomegaly 
sometimes accompanied by systemic lymphoadenopathy. In contrast to extra-nodal NK cell 
lymphoma, skin lesions are uncommon. The clinical progression is devastating despite 
treatment, and most patients survive for only days to weeks. Disseminated intravascular 
coagulation and hemophagocytic syndrome are often seen during the course of disease 
(Oshimi, 2007). In tissue sections, the neoplastic infiltrate is diffuse and destructive with 
lymphoid cell population usually appearing monomorphous (Siu, Chan & Kwong, 2002). 
Morphologically, leukemic cells are slightly larger than normal LGLs (Oshimi,  2007). There is 
an ample amount of pale or slightly basophilic cytoplasm that contains fine or coarse 
azurophilic granules. These cells are sCD3-cCD3ε+CD56+CD16+ (75% of cases), CD57- CD94+ 
with a germ line configuration of  and  genes of TCR. The chemokine system plays a critical 
role in the tumor cell diffusion, leading to the fulminant clinical courses. Serum levels of 
soluble FasL, IL-8, MIP-1, and MIP-1 are significantly elevated in ANKL patients and 
proliferating cells are highly positive for Fas, IL-8, RANTES, MIP-1, and MIP-1 (Makishima 
et al., 2007). Although clonal EBV is found in tumour cells in most patients and EBV is 
considered to be the etiological agent (Oshimi, 2007), little is known about the mechanisms 
through which EBV infection triggers clonal proliferation of NK cells. A defective T cell and 
NK cell response to EBV infection may play a role in the development of this disorder. 
However up to 10% of cases have been shown to be EBV-negative (Suzuki et al., 2004). 
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Several chromosomal abnormalities have been reported. In particular, the finding of 
abnormalities involving del(6q) in aggressive NK cell leukemia and in extranodal NK/T 
lymphoma provides a biological link between these two diseases (Wong, Chan  & Kwong, 
1997). A recent array-based comparative genomic hybridization study on 27 NK cell 
lymphoma/leukemia cases, classified into two disease groups based on the World Health 
Organization Classification (10 ANKL cases and 17 extranodal NK/T lymphomas, nasal 
type), showed recurrent gain of 1q and loss of 7p15.1–p22.3 and 17p13.1 in ANKL 
(Nakashima et al., 2005). The same study also demonstrated clear genetic differences 
between aggressive NK cell leukemia and extranodal NK/T cell lymphoma, suggesting that 
these are two separate entities (Nakashima et al., 2005).  
Aggressive NK cell leukemia is a catastrophic disease with an almost uniform mortality. A 
few patients have a clinical response with conventional chemotherapy (Kwong, 2005), 
although the response is typically transient and survival is measured in days to weeks. 
Allogeneic HSCT results in short-term remission in a few patients (Kwong, 2005). Taking 
together, big efforts for the recognition of new therapeutical targets and for development of 
new experimental protocols are urgently required to address the issue of ANKL therapy. As 
a matter of fact, recent data in a murine model have reported impressive response by 
targeting of survivin by nanoliposomal ceramide (Liu et al., 2010). 
4.2.3 Chronic lymphoproliferative disorder of NK cells (provisional) 
The chronic lymphoproliferative disorders of NK cells (CLPD-NK) are included among the 
novelties of the current WHO classification (Villamor et al., 2008). These rare and 
heterogeneous disorders are characterized by a chronic expansion of mature appearing NK 
cells (usually more than 2,000/l) in peripheral blood for more than 6 months (Loughran, 
1993; Semenzato et al., 1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi, 1996), 
without a clearly identified cause (Figure 2). Patients are usually adults with a mean age of 
60 years without gender and racial predisposition (Pandolfi et al., 1990). In recent years 
several studies have been published focusing on the pathogenetic mechanisms of this 
disease (Zambello & Semenzato, 2009; Loughran et al., 1997; Zambello et al., 2003; Hodge et 
al., 2009; Gattazzo et al., 2010; Epling-Burnette et al., 2008). NK cell activation in response to 
an unknown stimulus, likely of viral origin, is postulated to play a role in the initial steps of 
CLPD-NK by selecting NK clones (Zambello & Semenzato, 2009). No prototypical HTLV 
infection was demonstrated in these patients. However, the evidence that sera from a series 
of patients from Europe and USA reacted with the recombinant HTLV env protein p21E, 
suggests that exposure to a protein containing homology to BA21 may be important in the 
pathogenesis of this lymphoproliferative disorder (Loughran et al., 1997). In contrast with 
other mature NK cell neoplasms, EBV is not usually detected within affected lymphocytes 
(Zambello & Semenzato, 2009). It is believed that BM, which is frequently involved in 
CLPD-NK patients, represents the setting where the putative inciting antigen could reside. 
In this compartment, DCs may represent the target of infection (Zambello et al., 2005). Bone 
marrow biopsies demonstrated a topographic distribution of DCs and NK cells that 
indicates a close contact between the two cell types (Zambello et al., 2005). Patients' NK cells 
also showed a reduced capability of promoting Mo-DC maturation and of killing iDC  
(Balsamo et al., 2009). These findings could be explained, at least in part, by the low 
expression levels of NKp30 activating receptor, usually involved in the molecular 
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interactions occurring between NK cells and DC. It is suggested that impairment of DC 
killing capabilities detected in patients' NK-GLs may allow an accumulation of DC that, at 
certain sites, may sustain the chronic proliferation of NK cells themselves. DCs are also 
likely to represent the source of IL-15 that is crucial in the mechanisms sustaining the 
maintenance of NK proliferation. IL-15 has been found to mediate its activity by interfering 
with Bcl-2 family members, and more specifically by modulating  Bid expression (Hodge et 
al., 2009). Hodge et al., demonstrated that CLPD-NK cells express low levels of Bid, that are 
reversed by blockade of IL-15 signaling (Hodge et al., 2009). Bid is also increased following 
bortezomib (Velcade/PS341) treatment and this effect is coordinate with increased 
susceptibility to Fas- or TRAIL- independent apoptosis. In fact, bortezomib increased cell 
surface expression of DR4, a TRAIL death receptor decoy. The inability of death receptors to 
account for the apoptosis may be explained by the putative role of Bid in DNA damage and 
repair. It is possible that elevation of Bid expression in CLPD-NK cells promotes S phase cell 
cycle block and death (Hodge et al., 2009).  
A genetic susceptibility for this disease has been suggested and has been related to the 
detection of type B KIR gene repertoire which is characterized by a high number of activating 
genes (Zambello & Semenzato, 2009). In fact, a restricted pattern of KIR expression has 
usually been reported in these patients. A typical feature is the preferential expression of the 
KIR activating receptor isoforms and this pattern correlates with a reduced expression of 
other activating receptors, such as NCRs (Zambello et al., 2003). Together with a bias 
towards activating KIR expression, a deep silencing of inhibitory KIR through increased 
gene methylation has been recently demonstrated by our group (Gattazzo et al., 2010). More 
specifically, we showed the complete lack of KIR3DL1 expression in most analyzed patients, 
being the receptor expressed in 13% of patients as compared to 90% of controls (p<0.01). 
Interestingly, the results of methylation patterns of KIR3DL1 promoter showed a 
significantly higher methylation status (0.76 ± 0.12 SD) in the patients with respect to the 
healthy subjects (0.49 ± 0.10 SD, p<0.01). These data suggest that together with the increased 
expression of activating receptors, the lack of the inhibitory signal could also play a role in 
the pathogenesis of disease (Gattazzo et al., 2010). Recent data on the pathogenesis of CLPD-
NK are summarized in Figure 2. 
Biochemical studies on the mechanisms sustaining the growth of NK cells in these patients 
have demonstrated a role of RAS farnesil transferase (Epling-Burnette et al., 2008), with 
clinical implications (see below). Pathological NK cells express CD16 and usually low levels 
of CD56 and CD57. As expected, cells express TIA1, granzyme and perforins, which 
correlate with the cytotoxic potential of these cells. CD94 is expressed at high density on 
patients’ NK cells, frequently associated with the inhibitory subunit NKG2A, although, in a 
relevant number of cases, the dimer CD94/NKG2C has been reported (Zambello & 
Semenzato, 2003). Patients’ NK cells express functional  and  chains of IL-2/IL-15 
receptor, which are strictly related to the role of these cytokines in the pathogenesis of 
disease (Zambello & Semenzato, 2009).  
Most patients are asymptomatic, and the disease has a chronic indolent clinical course, 
similar to that reported for patients with T-LGL leukemia (Loughran, 1993; Semenzato et al., 
1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi 1996). In some cases this disorder is 
associated with other conditions, including pure red cell aplasia, vasculitic syndromes, solid 
and hematologic tumors, splenectomy, neuropathy and autoimmune disorders (Loughran, 
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1993; Semenzato et al., 1987; Tefferi et al., 1994; Semenzato et al., 1997; Oshimi, 1996). 
Recently, in patients with chronic myelogenous leukaemia, the association has been 
reported between treatment with dasatinib and the development of CLPD-NK. It has been 
suggested that the development of CLPD-NK might contribute on the control of Ph positive 
leukemic cells proliferation (Kim et al., 2009). Systemic symptoms, such as cytopenia (mostly 
neutropenia and anemia), are rare. Lymphoadenopathy, hepatomegaly, splenomegaly and 
cutaneous lesions are uncommon. Occasionally, patients present a slow progressive increase 
of peripheral blood NK cells and organ involvement. Several cases with a spontaneous 
complete remission have been reported (Zambello & Semenzato, 2009). Cytologically, the 
circulating cells show typical granular lymphocyte  morphology, with moderate amount of 
pale cytoplasm that contains > 3 azurophilic granules. Bone marrow biopsy is characterized 
by interstitial infiltration of cells with small nuclei and pale cytoplasm, which are difficult to 
recognize without the help of immunohistochemical techniques. Cytogenetic is normal in 
most cases (Zambello & Semenzato, 2009) and the germ line configuration of TCR is 
demonstrated, as expected for normal NK cells. Since clonality of proliferating cells is 
difficult to detect in these patients, the analysis of restriction fragment length polymorphism 
(RLFP) has been used as an indirect marker to demonstrate the clonality in some but not all 
patients. In rare case, in which EBV can be demonstrated in plasmid form within NK cells, 
the clonality of cells might be easily examined by Southern Blot analysis using probes 
recognizing the EBV terminal repeats (Kawa-Ha et al., 1989). Patients with CLPD-NK 
usually have an indolent clinical course and respond to immunosuppressive therapy with 
low doses of methotrexate (usually 10 mg/m2/week) or of cyclophosphamide (50 or 100 
mg/day) or cyclosporin (3-5 mg/kg/day) with or without inclusion of  low doses of 
steroids (Lamy & Loughran, 2011). 
 
 
Fig. 2. Possible mechanisms of CLPD-NK pathogenesis. 
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5. Conclusions 
NK cells are bone marrow–derived granular lymphocytes that have a key role in the 
recognition and in the killing of tumor- or virus-infected cells. The identification of a large 
array of surface NK receptors capable of transducing inhibitory or activating signals, let to 
explain how their effector functions could be regulated.  
In recent years, it has also been shown that NK cells may play a role in the regulation of the 
immune response. This has been based on the finding that NK cells were able to functionally 
interact with different cells of the innate immune system including DCs, pDCs and 
macrophages. Besides the well known CD56dimCD16+ cytotoxic PB NK cells, different NK 
cell subsets located in specific tissue/organ compartments have been shown to exert 
various, alternative, regulatory functions. NK cells homing in SLT promote Th1 
polarization. Conversely, decidual NK cells favour Treg expansion and play an important 
role in tissue remodelling and neo-angiogenesis process. In MALT, NK22 cells may support 
immune defence against bacteria invasion by their peculiar cytokine and chemokine 
secreting profile.  
Whether the above described different NK cell subsets may derive from the same lineage or 
from different ones, is still a matter of debate. Studies on NK cell development may help to 
clarify the possible lineage relationship between the different NK cell subsets. In vitro 
models of NK cell development helped to define phenotypically and functionally different 
maturation stages that were, at least in part, confirmed by in vivo analysis. For example, the 
CD56brightCD16-CD94/NKG2A+KIR- subset, that is largely represented at the end on in vitro 
development, represents the first wave of lymphocytes appearing in PB at early time 
intervals after HSCT. NK cells originate from CD34+ hematopoietic precursors but several 
experimental evidences suggest that the NK cell development and terminal maturation does 
not occur wholly in the BM. Other  secondary lymphoid organs, including L.N. and MALT, 
as well as decidua, may represent sites where  NK cell development occurs. This suggest 
how defined subsets of NK cells may differentiate in peculiar tissues and point the attention 
on the role of the microenvironment in such a process. The full characterization of the 
genetic and epigenetic factors that may contribute to determine the type of NK cell that will 
develop is still in process and it will be important also to better define mechanisms leading 
to NK cell malignant transformation. 
It is hopeful that investigation on NK cell neoplasm pathogenesis could lead to identify 
molecular targets and discovery of more efficient and less toxic treatments. The elucidation 
of pathways by which EBV transform NK cells might help to identify new molecular targets. 
Furthermore, the mechanisms of resistance to therapy, including alteration of apoptosis 
pathways should be deeply characterized. Thus, the definition the NK neoplasm patho-
physiology and the identification of possible biological targets may help to improve 
therapeutical approaches. 
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